Study design
DYSPLASTIC, CERVICAL CANCER, -20
This randomized, multicenter, double-blind, parallel, three-group controlled, superiority trial tested the efficacy of single-dose bivalent (HPV 16/18) and single-dose nonavalent (HPV 16/18/31/33/45/52/58/6/11) HPV vaccination, as described in the published protocol paperIn GAVI-funded countries, including Kenya, multi-dose HPV vaccination is offered to 9–14-year-old girls through the national immunization program. Catch-up vaccination for adolescent girls and young women 15 years of age and older is not provided. Cervical cancer screening is offered to older women instead. We conducted a clinical trial to test the efficacy of single-dose HPV vaccination among young women aged 15-20 years within the context of cytological screening for dysplastic lesions. This was determined to be ethical, as vaccination for this age group in Kenya and many low-HDI countries is not currently supported through national programs or global immunization bodies